Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lionel Adès

Showing results (1-10 of 130) with videos related to

Pageof 13
Sort By:
Bulletin Du Cancer|July 5, 2023
[Treating high-risk myelodysplastic syndromes]Lionel Adès
Hematology. American Society of Hematology. Education Program|December 14, 2011
Immunomodulating drugs in myelodysplastic syndromesLionel Adès, Pierre Fenaux
Best Practice & Research. Clinical Haematology|February 11, 2014
Hypomethylating agents and chemotherapy in MDSLionel Adès, Valeria Santini
Blood|April 12, 2013
How we treat lower-risk myelodysplastic syndromesPierre Fenaux, Lionel Adès
Current Hematologic Malignancy Reports|April 29, 2010
Is cytarabine required in the treatment of acute promyelocytic leukemia?Lionel Adès, Pierre Fenaux
Expert Review of Hematology|October 19, 2018
An update on treatment of higher risk myelodysplastic syndromesRamy Rahmé, Lionel Adès
Lancet (London, England)|March 25, 2014
Myelodysplastic syndromesLionel Adès, Raphael Itzykson, Pierre Fenaux
Seminars in Hematology|October 20, 2012
Treatment of advanced myelodysplastic syndrome with demethylating agents: azacitidineLionel Adès, Raphael Itzykson, Pierre Fenaux
Cancer Journal (Sudbury, Mass.)|January 24, 2022
The Evolution of Research and Therapy With Hypomethylating Agents in Acute Myeloid Leukemia and Myelodysplastic Syndrome: New Directions for Old DrugsNicholas J Short, Hervé Dombret, Lionel Adès, et al.
European Journal of Haematology|October 12, 2023
MDS/CMML from resource-limited region: Characteristics and comparison to tertiary reference European centerAnna Sevoyan, Arsène Mekinian, Fatiha Chermat, et al.
Pageof 13

Showing results (1-10 of 130) with videos related to

Sort By:
Pageof 13
Bulletin Du Cancer|July 5, 2023
[Treating high-risk myelodysplastic syndromes]Lionel Adès
Hematology. American Society of Hematology. Education Program|December 14, 2011
Immunomodulating drugs in myelodysplastic syndromesLionel Adès, Pierre Fenaux
Best Practice & Research. Clinical Haematology|February 11, 2014
Hypomethylating agents and chemotherapy in MDSLionel Adès, Valeria Santini
Blood|April 12, 2013
How we treat lower-risk myelodysplastic syndromesPierre Fenaux, Lionel Adès
Current Hematologic Malignancy Reports|April 29, 2010
Is cytarabine required in the treatment of acute promyelocytic leukemia?Lionel Adès, Pierre Fenaux
Expert Review of Hematology|October 19, 2018
An update on treatment of higher risk myelodysplastic syndromesRamy Rahmé, Lionel Adès
Lancet (London, England)|March 25, 2014
Myelodysplastic syndromesLionel Adès, Raphael Itzykson, Pierre Fenaux
Seminars in Hematology|October 20, 2012
Treatment of advanced myelodysplastic syndrome with demethylating agents: azacitidineLionel Adès, Raphael Itzykson, Pierre Fenaux
Cancer Journal (Sudbury, Mass.)|January 24, 2022
The Evolution of Research and Therapy With Hypomethylating Agents in Acute Myeloid Leukemia and Myelodysplastic Syndrome: New Directions for Old DrugsNicholas J Short, Hervé Dombret, Lionel Adès, et al.
European Journal of Haematology|October 12, 2023
MDS/CMML from resource-limited region: Characteristics and comparison to tertiary reference European centerAnna Sevoyan, Arsène Mekinian, Fatiha Chermat, et al.
Pageof 13